X-Therma, a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has completed an oversubscribed $22.4 million Series B funding round. The investment enables X-Therma to scale global commercial operations and facilitates the company's progression into the clinical stage with Food and Drug Administration (FDA) Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations.

The round was co-led by new investor Starling Locke Capital, fully supported by Series A lead investor, LOREA AG, along with participation from new and existing investors.

X-Therma Inc. is pioneering breakthrough cold chain technology via a convergent biopreservation platform, to advance regenerative medicine and make available safe and on-demand organs, engineered tissues, cell and gene therapies, vaccines, and beyond to patients in need. Headquartered in Hercules, part of the San Francisco Bay Area and an expanding presence in Austria, X-Therma's technology is poised to become a paradigm shift that enables worldwide organ sharing and eliminates organ waiting lists across the globe.